Veracyte Announces Second Quarter 2015 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Wall Street ends sharply higher as AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- Wall Street ends sharply higher as AI optimism reignites and Treasury yields retreat
Piper Jaffray Trims PT on Veracyte (VCYT) to $12, Maintains 'Overweight'
August 14, 2015 7:33 AM EDTPiper Jaffray analyst William Quirk reiterated an Overweight rating but trimmed his price target on Veracyte, Inc (NASDAQ: VCYT) to $12.00 (from $13.00) following Q3 results and outook.
Quirk commented, "Veracyte reported a 37.2% yoy revenue increase to $11.9M, above our $11.7M estimate, but below... More
Veracyte (VCYT) Misses Q2 EPS by 4c
August 13, 2015 4:35 PM EDTVeracyte (NASDAQ: VCYT) reported Q2 EPS of ($0.35), $0.04 worse than the analyst estimate of ($0.31). Revenue for the quarter came in at $11.9 million versus the consensus estimate of $12.23 million.
Veracyte reaffirmed FY2015 guidance.
"We continue to see strong growth of Afirma across both community-based physicians... More
